Publication

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426

Powles, T.
; 
Plimack, E. R.
; 
Stus, V.
; 
Waddell, Thomas
; 
Gafanov, R.
; 
Pouliot, F.
; 
Nosov, D.
; 
Melichar, B.
; 
Soulieres, D.
; 
Borchiellini, D.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Powles, T.
Plimack, E. R.
Stus, V.
Waddell, Thomas
Gafanov, R.
Pouliot, F.
Nosov, D.
Melichar, B.
Soulieres, D.
Borchiellini, D.
Vynnychenko, I.
McDermott, R. S.
Azevedo, S. J.
Tamada, S.
Kryzhanivska, A.
Li, C.
Burgents, J. E.
Molife, L. R.
Rini, B. I.
Bedke, J.
Affiliation
Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, and Queen Mary University of London, London
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Powles T, Plimack ER, Stus V, Waddell T, Gafanov R, Pouliot F, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301334.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/625803
Embedded videos